NZ590919A - Vaccine against hpv - Google Patents

Vaccine against hpv

Info

Publication number
NZ590919A
NZ590919A NZ590919A NZ59091909A NZ590919A NZ 590919 A NZ590919 A NZ 590919A NZ 590919 A NZ590919 A NZ 590919A NZ 59091909 A NZ59091909 A NZ 59091909A NZ 590919 A NZ590919 A NZ 590919A
Authority
NZ
New Zealand
Prior art keywords
vaccine
dose
hpv
vaccine against
against hpv
Prior art date
Application number
NZ590919A
Other languages
English (en)
Inventor
Dominique Descamps
Sandra Giannini
Nicolas Lecrenier
Jean Stephenne
Martine Anne Cecile Wettendorff
Original Assignee
Glaxosmithkline Biolog Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxosmithkline Biolog Sa filed Critical Glaxosmithkline Biolog Sa
Publication of NZ590919A publication Critical patent/NZ590919A/xx

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/12Viral antigens
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/20Antivirals for DNA viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/04Immunostimulants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/51Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525Virus
    • A61K2039/5258Virus-like particles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/545Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/555Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505Inorganic adjuvants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/555Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511Organic adjuvants
    • A61K2039/55572Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/70Multivalent vaccine
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011Details
    • C12N2710/20011Papillomaviridae
    • C12N2710/20034Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
NZ590919A 2008-07-31 2009-07-29 Vaccine against hpv NZ590919A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US8510108P 2008-07-31 2008-07-31
US17656109P 2009-05-08 2009-05-08
PCT/EP2009/059820 WO2010012780A1 (en) 2008-07-31 2009-07-29 Vaccine against hpv

Publications (1)

Publication Number Publication Date
NZ590919A true NZ590919A (en) 2012-10-26

Family

ID=41139260

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ590919A NZ590919A (en) 2008-07-31 2009-07-29 Vaccine against hpv

Country Status (26)

Country Link
US (1) US20110189229A1 (enExample)
EP (1) EP2318042B1 (enExample)
JP (1) JP6022159B2 (enExample)
KR (1) KR20110053340A (enExample)
CN (1) CN102159239A (enExample)
AU (1) AU2009275909A1 (enExample)
BR (1) BRPI0916732B1 (enExample)
CA (1) CA2732436C (enExample)
CO (1) CO6341567A2 (enExample)
DK (1) DK2318042T3 (enExample)
DO (1) DOP2011000031A (enExample)
EA (1) EA201170264A1 (enExample)
ES (1) ES2519490T3 (enExample)
HR (1) HRP20141063T1 (enExample)
IL (1) IL210977A0 (enExample)
MA (1) MA32554B1 (enExample)
MX (1) MX2011001218A (enExample)
NZ (1) NZ590919A (enExample)
PE (1) PE20110327A1 (enExample)
PL (1) PL2318042T3 (enExample)
PT (1) PT2318042E (enExample)
RS (1) RS53607B1 (enExample)
SI (1) SI2318042T1 (enExample)
SM (1) SMT201400170B (enExample)
WO (1) WO2010012780A1 (enExample)
ZA (1) ZA201100889B (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2010264695A1 (en) 2009-06-25 2012-01-19 Glaxosmithkline Biologicals S.A. Novel human papillomavirus (HPV) protein constructs and their use in the prevention of HPV disease
CN102178944A (zh) * 2010-09-17 2011-09-14 大连雅立峰生物制药有限公司 人乳头瘤病毒16和18型l1蛋白在昆虫细胞中的表达及应用
CN102229660B (zh) * 2011-05-25 2015-04-22 厦门大学 截短的人乳头瘤病毒33型l1蛋白
KR101559622B1 (ko) * 2012-07-30 2015-10-13 중앙대학교 산학협력단 인유두종바이러스 바이러스 유사입자의 고효율 정제방법
AU2015313756A1 (en) * 2014-09-11 2017-03-09 Cadila Healthcare Limited Superior human papilloma virus antigens with superior immunological properties and vaccine containing it
US10063211B2 (en) 2016-02-03 2018-08-28 Qualcomm Incorporated Compact bypass and decoupling structure for millimeter-wave circuits
RU2628693C1 (ru) * 2016-11-10 2017-08-21 федеральное государственное бюджетное учреждение "Федеральный научно-исследовательский центр эпидемиологии и микробиологии имени почетного академика Н.Ф. Гамалеи" Министерства здравоохранения Российской Федерации (ФГБУ "ФНИЦЭМ им. Н.Ф. Гамалеи" Минздрава России) РЕКОМБИНАНТНЫЙ ГЕН L1HPV16, РЕКОМБИНАНТНАЯ ПЛАЗМИДА pQE-L1/16, БЕЛОК L1HPV16 И ИХ ПРИМЕНЕНИЕ
US20210302427A1 (en) * 2020-03-31 2021-09-30 Shuhari Group, LLC Secure Immunity Information Transmission System And Network
WO2025147639A1 (en) * 2024-01-04 2025-07-10 Cyanvac Llc Improved formulation providing increased stability for vaccines composition

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9921146D0 (en) * 1999-09-07 1999-11-10 Smithkline Beecham Biolog Novel composition
WO2005089164A2 (en) * 2003-12-31 2005-09-29 Pharmexa Inc. Inducing cellular immune responses to human papillomavirus using peptide and nucleic acid compositions
US7758866B2 (en) * 2004-06-16 2010-07-20 Glaxosmithkline Biologicals, S.A. Vaccine against HPV16 and HPV18 and at least another HPV type selected from HPV 31, 45 or 52
WO2005123125A1 (en) * 2004-06-16 2005-12-29 Glaxosmithkline Biologicals S.A. Vaccine against hpv16 and hpv18 and at least another hpv type selected from hpv 31, 45 or 52
WO2006114312A2 (en) * 2005-04-26 2006-11-02 Glaxosmithkline Biologicals S.A. Vaccine

Also Published As

Publication number Publication date
ZA201100889B (en) 2012-04-25
DOP2011000031A (es) 2011-02-28
AU2009275909A1 (en) 2010-02-04
CA2732436A1 (en) 2010-02-04
PE20110327A1 (es) 2011-06-29
EP2318042A1 (en) 2011-05-11
PT2318042E (pt) 2014-11-05
WO2010012780A1 (en) 2010-02-04
HRP20141063T1 (hr) 2015-01-02
MX2011001218A (es) 2011-03-15
ES2519490T3 (es) 2014-11-07
IL210977A0 (en) 2011-04-28
CO6341567A2 (es) 2011-11-21
MA32554B1 (fr) 2011-08-01
JP2011529475A (ja) 2011-12-08
BRPI0916732A2 (pt) 2017-01-31
SMT201400170B (it) 2015-01-15
RS53607B1 (sr) 2015-04-30
JP6022159B2 (ja) 2016-11-09
PL2318042T3 (pl) 2015-02-27
CA2732436C (en) 2018-01-16
KR20110053340A (ko) 2011-05-20
DK2318042T3 (da) 2014-11-10
CN102159239A (zh) 2011-08-17
EA201170264A1 (ru) 2011-08-30
SI2318042T1 (sl) 2014-12-31
EP2318042B1 (en) 2014-08-20
US20110189229A1 (en) 2011-08-04
BRPI0916732B1 (pt) 2021-06-29

Similar Documents

Publication Publication Date Title
NZ590919A (en) Vaccine against hpv
MD4430B1 (ro) Compoziţii şi metode de tratament al hepatitei virale C
NZ606993A (en) Combination pharmaceutical composition and methods of treating and preventing the infectious diseases
EP2444103A4 (en) UTERUS COLON CANCER VACCINE
NZ597378A (en) Treatment of multiple sclerosis with laquinimod
NZ589445A (en) Rasagiline for parkinson's disease modification
PH12019500025A1 (en) Cancer treatment combinations
HK1198703A1 (en) Hpv chimaeric particle
EP2216024A3 (en) Use of Ranolazine for the treatment of cardiovascular diseases
AR090885A1 (es) Uso de laquinimod en alta dosis para el tratamiento de la esclerosis multiple
MX2012008652A (es) Terapias para tratar infeccion por virus de hepatitis c.
JP2011529475A5 (enExample)
NZ598465A (en) Dosage regimens for hcv combination therapy comprising bi201335, interferon alpha and ribavirin
WO2021156404A3 (en) Treatment of hpv-related diseases
IL182440A0 (en) Subtype-matched inactivated whole virus vaccines for treating patients with hiv infection
WO2010045431A3 (en) Dry powder formulations, vaccines and methods
NZ588655A (en) Treatment of hepatitis c virus infections with telaprevir (vx-950) in patients non-responsive to treatment with pegylated interfer0n-alpha-2a/2b and ribavirin
JP2013523886A5 (enExample)
EP1778209B8 (en) Methods and compositions for oral delivery of fts
CN103096885A (zh) 不饱和脂肪酸用于抑制病毒复制和/或感染的用途
NZ580603A (en) Intradermal influenza vaccine
Vierling et al. High Efficacy at Lower Doses of MK-5172 25 mg and 50 mg Daily for 12 Weeks in HCV Genotype (G) 1 Treatment-Naive Non-cirrhotic Patients: 1123
CN201949352U (zh) 便捷服药器
Devoti et al. Chemokine Mediated Immune Evasion by Human Papillomavirus (HPV) in Recurrent Respiratory Papillomatosis (RRP)
MD3121G2 (ro) Metodă de profilaxie a hepatitei virale B

Legal Events

Date Code Title Description
PSEA Patent sealed
RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 3 YEARS UNTIL 29 JUL 2016 BY THOMSON REUTERS

Effective date: 20130719

LAPS Patent lapsed